International Journal of Radiation Oncology * Biology * Physics
Volume 67, Issue 3 , Pages 823-827 , 1 March 2007

X-ray–assisted positioning of patients treated by conformal arc radiotherapy for prostate cancer: Comparison of setup accuracy using implanted markers versus bony structures

  • Guy Soete, M.D.

      Affiliations

    • Department of Radiotherapy, Academic Hospital Free University of Brussels, Brussels, Belgium
    • Corresponding Author InformationReprint requests to: Guy Soete, M.D., Department of Radiotherapy, Oncology Center, Academic Hospital Free University of Brussels (AZ VUB), Laarbeeklaan 101, B-1090 Brussels, Belgium. Tel: (+32) 2-477-6144; Fax: (+32) 2-477-6212
    • ,
  • Mieke De Cock, Ph.D.

      Affiliations

    • Department of Radiotherapy, Academic Hospital Free University of Brussels, Brussels, Belgium
    • ,
  • Dirk Verellen, Ph.D.

      Affiliations

    • Department of Radiotherapy, Academic Hospital Free University of Brussels, Brussels, Belgium
    • ,
  • Dirk Michielsen, M.D.

      Affiliations

    • Department of Urology, Academic Hospital Free University of Brussels, Brussels, Belgium
    • ,
  • Frans Keuppens, M.D.

      Affiliations

    • Department of Urology, Academic Hospital Free University of Brussels, Brussels, Belgium
    • ,
  • Guy Storme, Ph.D.

      Affiliations

    • Department of Radiotherapy, Academic Hospital Free University of Brussels, Brussels, Belgium

Received 18 April 2006 ,Revised 24 August 2006 ,Accepted 22 September 2006.

References 

  1. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097–1105
  2. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. J Am Med Assoc. 2005;294:1233–1239
  3. Peeters STH, Heemsbergen WD, Koper PCM, et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24:1190–1996
  4. Schultheiss TE, Lee WR, Hunt MA, et al. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys. 1997;37:3–11
  5. Boersma LJ, van den Brink M, Bruce AM, et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70–78 Gy) conformal radiotherapy for prostate cancer, using dose–volume histograms. Int J Radiat Oncol Biol Phys. 1998;41:83–92
  6. Storey MR, Pollack A, Zagars G, et al. Complications from radiotherapy dose-escalation in prostate cancer: Preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys. 2000;48:635–642
  7. Peeters ST, Heemsbergen WD, van Putten WL, et al. Acute and late complications after radiotherapy for prostate cancer: Results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys. 2005;61:1019–1034
  8. International Commission on Radiation Units and Measurements. Prescribing, recording and reporting photon beam therapy (ICRU Report 50). 1993;Bethesda, MD
  9. van Herk M, Remeijer P, Rasch C, et al. The probability of correct target dosage: Dose–population histograms for deriving treatment margins in radiotherapy. Int J Radiat Oncol Biol Phys. 2000;47:1121–1135
  10. Soete G, Verellen D, Michielsen D, et al. Clinical use of stereoscopic X-ray positioning of patients treated with conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2002;54:948–952
  11. Verellen D, Soete G, Linthout N, et al. Quality assurance of a system for improved target localization and patient setup that combines real-time infrared tracking and stereoscopic X-ray imaging. Radiother Oncol. 2003;67:129–141
  12. Soete G, Van de Steene J, Verellen D, et al. Initial clinical experience with infrared reflecting skin markers in the positioning of patients treated by conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2002;52:694–698
  13. Verellen D, Linthout N, Soete G, et al. Considerations on treatment efficiency of different conformal radiation therapy techniques for prostate cancer. Radiother Oncol. 2002;63:27–36
  14. Kutcher GJ, Mageras GS, Leibel SA. Control, correction, and modeling of setup errors and organ motion. Semin Radiat Oncol. 1995;5:134–145
  15. Balter JM, Lam KL, Sandler HM, et al. Automated localization of the prostate at the time of treatment using implanted radiopaque markers: Technical feasibility. Int J Radiat Oncol Biol Phys. 1995;33:1281–1286
  16. Crook JM, Raymond Y, Salhani D, et al. Prostate motion during standard radiotherapy as assessed by fiducial markers. Radiother Oncol. 1995;37:35–42
  17. Nederveen AJ, van der Heide UA, Dehnad H, et al. Measurements and clinical consequences of prostate motion during a radiotherapy fraction. Int J Radiat Oncol Biol Phys. 2002;53:206–214
  18. Aubry J, Beaulieu L, Girouard L, et al. Measurements of intrafraction motion and interfraction and intrafraction rotation of prostate by three-dimensional analysis of daily portal imaging with radiopaque markers. Int J Radiat Oncol Biol Phys. 2004;60:30–39
  19. Schallenkamp JM, Herman MG, Kruse JJ, et al. Prostate position relative to pelvic bony anatomy based on intraprostatic gold markers and electronic portal imaging. Int J Radiat Oncol Biol Phys. 2005;63:800–811
  20. Shimizu S, Shirato H, Kitamura K, et al. Use of an implanted marker and real-time tracking of the marker for the positioning of prostate and bladder cancers. Int J Radiat Oncol Biol Phys. 2000;48:1591–1597
  21. Litzenberg D, Dawson LA, Sandler H, et al. Daily prostate targeting using implanted radiopaque markers. Int J Radiat Oncol Biol Phys. 2002;52:699–703
  22. Herman MG, Pisansky TM, Kruse JJ, et al. Technical aspects of daily online positioning of the prostate for three-dimensional conformal radiotherapy using an electronic portal imaging device. Int J Radiat Oncol Biol Phys. 2003;57:1131–1140
  23. Serago CF, Buskirk SJ, Igel TC, et al. Comparison of daily megavoltage electronic portal imaging or kilovoltage imaging with marker seeds to ultrasound imaging or skin marks for prostate localization and treatment positioning in patients with prostate cancer. Int J Radiat Oncol Biol Phys. 2006;65:1585–1592
  24. Van den Heuvel F, Fugazzi J, Seppi E, et al. Clinical application of a repositioning scheme, using gold markers and electronic portal imaging. Radiother Oncol. 2006;79:94–100
  25. Padhani AR, Khoo VS, Suckling J, et al. Evaluating the effect of rectal distension and rectal movement on prostate gland position using cine MRI. Int J Radiat Oncol Biol Phys. 1999;44:525–533
  26. Huang E, Dong L, Chandra A, et al. Intrafraction prostate motion during IMRT for prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53:261–268
  27. Kitamura K, Shirato H, Shimizu S, et al. Registration accuracy and possible migration of internal fiducial gold marker implanted in prostate and liver treated with real-time tumor-tracking radiation therapy (RTRT). Int J Radiat Oncol Biol Phys. 1999;43:719–725
  28. Pouliot J, Aubin M, Langen KM, et al. (Non)-migration of radiopaque markers used for on-line localization of the prostate with an electronic portal imaging device. Int J Radiat Oncol Biol Phys. 2003;56:862–866
  29. Poggi MM, Gant DA, Sewchand W, et al. Marker seed migration in prostate localization. Int J Radiat Oncol Biol Phys. 2003;56:1248–1251
  30. Dehnad H, Nederveen AJ, van der Heide UA, et al. Clinical feasibility study for the use of implanted gold seeds in the prostate as reliable positioning markers during megavoltage irradiation. Radiother Oncol. 2003;67:295–302
  31. Kupelian PA, Willoughby TR, Meeks SL, et al. Intraprostatic fiducials for localization of the prostate gland: Monitoring intermarker distances during radiation therapy to test for marker stability. Int J Radiat Oncol Biol Phys. 2005;62:1291–1296
  32. Bergström P, Löfroth P, Widmark A. High-precision conformal radiotherapy (HPCRT) of prostate cancer—a new technique for exact positioning of the prostate at the time of treatment. Int J Radiat Oncol Biol Phys. 1998;42:305–311
  33. Fransson P, Bergström P, Löfroth PO, et al. Prospective evaluation of urinary and intestinal side effects after BeamCath stereotactic dose-escalated radiotherapy of prostate cancer. Radiother Oncol. 2002;63:239–248
  34. Teh BS, Mai WY, Uhl BM, et al. Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization: Acute toxicity and dose–volume analysis. Int J Radiat Oncol Biol Phys. 2001;49:705–712
  35. D’Amico AV, Manola J, Loffredo M, et al. A practical method to achieve prostate gland immobilization and target verification for daily treatment. Int J Radiat Oncol Biol Phys. 2001;51:1431–1436
  36. Wachter S, Gerstner N, Dorner D, et al. The influence of a rectal balloon tube as internal immobilization device on variations of volumes and dose–volume histograms during treatment course of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2002;52:91–100
  37. Miralbell R, Mollà M, Arnalte L, et al. Target repositioning optimization in prostate cancer: Is intensity-modulated radiotherapy under stereotactic conditions feasible?. Int J Radiat Oncol Biol Phys. 2004;59:366–371
  38. van Lin EN, van der Vight LP, Wijes JA, et al. The effect of an endorectal balloon and off-line correction on the interfraction systematic and random prostate position variations: A comparative study. Int J Radiat Oncol Biol Phys. 2005;61:278–288
  39. Morr J, DiPetrillo T, Tsai J, et al. Implementation and utility of a daily ultrasound-based localization system with intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53:1124–1129
  40. Serago CF, Chungbin SJ, Buskirk SJ, et al. Initial experience with ultrasound localization for positioning prostate cancer patients for external-beam radiotherapy. Int J Radiat Oncol Biol Phys. 2002;53:1130–1138
  41. Chandra , Dong L, Huang E, et al. Experience of ultrasound-based daily prostate localization. Int J Radiat Oncol Biol Phys. 2003;56:436–447
  42. Trichter F, Ennis RD. Prostate localization using transabdominal ultrasound imaging. Int J Radiat Oncol Biol Phys. 2003;56:1225–1233
  43. Langen KM, Pouliot J, Anezinos C, et al. Evaluation of ultrasound-based prostate localization for image-guided radiotherapy. Int J Radiat Oncol Biol Phys. 2003;57:635–644
  44. Van den Heuvel F, Powell T. Independent verification of ultrasound based image-guided radiation treatment, using electronic portal imaging and implanted gold markers. Med Phys. 2003;30:2878–2887
  45. Artignan X, Smitsmans MHP, Lebesque JV, et al. Online ultrasound image guidance for radiotherapy of prostate cancer: Impact of image acquisition on prostate displacement. Int J Radiat Oncol Biol Phys. 2004;59:595–601
  46. McGahan JP, Ryu J, Fogata M. Ultrasound probe pressure as a source of error in prostate localization for external-beam radiotherapy. Int J Radiat Oncol Biol Phys. 2004;60:788–793
  47. Smitsmans MH, Wolthaus JW, Artignan X, et al. Automatic localization of the prostate for on-line or off-line image-guided radiotherapy. Int J Radiat Oncol Biol Phys. 2004;60:623–635
  48. Smitsmans MH, de Bois J, Sonke JJ, et al. Automatic prostate localization on cone-beam CT scans for high-precision image-guided radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63:975–984
  49. Langen KM, Zhang Y, Andrews RD, et al. Initial experience with megavoltage (MV) CT guidance for daily prostate alignments. Int J Radiat Oncol Biol Phys. 2005;62:1517–1524
  50. Seiler PG, Blattmann H, Kirsch S, et al. A novel tracking technique for the continuous precise measurement of tumour positions in conformal radiotherapy. Phys Med Biol. 2000;45:103–110
  51. Balter JM, Wright JN, Newell LJ, et al. Accuracy of a wireless localization system for radiotherapy. Int J Radiat Oncol Biol Phys. 2005;61:933–1937
  52. Webb S. Motion effects in (intensity modulated) radiation therapy: A review. Phys Med Biol. 2006;51:403–425

 This study was supported in part by a grant from BrainLAB A.G., Heimstetten, Germany. NovalisBody is a product of BrainLAB A.G., Heimstetten, Germany.

 Conflict of interest: none.

PII: S0360-3016(06)03227-5

doi: 10.1016/j.ijrobp.2006.09.041

International Journal of Radiation Oncology * Biology * Physics
Volume 67, Issue 3 , Pages 823-827 , 1 March 2007

Article Tools